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ABSTRACT  
   
Coccidioidomycosis, also known as Valley Fever, is a disease caused by the dimorphic 
soil-dwelling fungus, Coccidioides sp. Coccidioidomycosis is difficult to diagnose 
because symptoms are similar to community-acquired pneumonia. Current diagnostic 
tests rely on antibody responses, but immune responses can be delayed and aberrant, 
resulting in false negative diagnoses. Unlike serology, detection of coccidioidal proteins 
or other fungal components in blood could distinguish valley fever from other pulmonary 
infections and provide a definitive diagnosis. Using mass spectrometry (LC-MS/MS) we 
examined the plasma peptidome from patients with serologically confirmed 
coccidioidomycosis. Mass spectra were searched using the protein database from the 
Coccidioides species, generated and annotated by the Broad Institute. 15 of 20 patients 
with serologically confirmed coccidioidomycosis demonstrated the presence of a peptide 
in plasma, "PGLDSKSLACTFSQV" (PGLD). The peptide is derived from an open 
reading frame from a "conserved hypothetical protein" annotated with 2 exons, and to 
date, found only in the C. posadasii strain Silviera RMSCC 3488 genomic sequence. In 
this thesis work, cDNA sequence analysis from polyadenylated RNA confirms the 
peptide sequence and genomic location of the peptide, but does not indicate that the 
intron in the gene prediction of C. posadasii strain Silviera RMSCC 3488 is present. A 
monoclonal antibody generated against the peptide bound to a 16kDa protein in T27K 
coccidioidal lysate. Detecting components of the fungus plasma could be a useful 
diagnostic tool, especially when serology does not provide a definitive diagnosis.
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CHAPTER 1 
INTRODUCTION  
 
1.1  Discovery of Coccidioidomycosis 
In 1892, Wernecke and Posadas described an illness in an Argentinean soldier in South 
America with cutaneous manifestations relating to a fungal pathogen.  A year after 
Posadas' initial report, a 40-year-old man entered a San Francisco hospital with skin 
lesions similar to those of Posadas' patient.  He was a manual laborer who immigrated to 
the San Joaquin Valley and in 1895 and, upon his death, an autopsy revealed numerous 
nodules occupied the lungs, adrenals, lymph nodes, liver, peritoneum, prostate, spleen, 
and testes. It was believed that the pathogen was protozoan by nature but in 1899 William 
Ophüls and Herbert C. Moffitt  discovered it to be a fungal pathogen.  The pathogen, 
Coccidioides immitis,  was not a protozoan but was a fungus that existed in 2 forms: 
mycelia and spherules containing endospores.  In 1929, a 26-year-old, second-year 
medical student, Harold Chope, who was studying C. immitis opened an old, desiccated 
culture.  He exhaled on the plate and a plume of spores arose.  Chope endured severe 
pleuritic chest pain nine days later along with purulent sputum.  He later developed 
erythema nodosum and his health recovered (Derensinski SC).  In 1932, soil samples 
were taken from and around the barracks in Kern County as many of the men were 
becoming ill.  Results indicated the soil contained C. immitis.  Another most important 
case, a graduate student by the name of Charles E. Smith, developed pleuritic chest pain 
that he thought might be tuberculosis.  He had, in fact, failed to diagnose his own case of 
2 
coccidioidomycosis.  He further went on to study migratory farm laborers who had come 
to California in the 1930s after escaping from the “Dust Bowl” of the Midwest 
(Hirschmann, J.). During 1940–1941, Smith studied the outbreak of coccidioidomycosis 
amoung Army Air Forces pilots airmen whose training grounds were located in the San 
Joaquin Valley.  Smith continued to study this endemic which revealed that 60% of 
infections were asymptomatic, and erythema nodosum occurred in ∼5% of men (Lewis 
GG and J Mewha).  Because of Pasadas work in the late 1800’s the name C. posadasii 
was dedicated.   
Coccidioidomycosis, or Valley Fever (VF), an understudied disease, is caused by a 
dimorphic fungus (Fig 1) endemic to the soils of Central and South America, Mexico, 
and the southwestern United States.  C. immitis, one of two known species of the 
ascomycete fungus, is found in the central valley of California.  C. posadasii is found in 
other areas such as Arizona, Texas, Mexico, and parts of Central and South America 
(Fisher MC, GL Koenig, TJ White, and JW Taylor).  It has been noted that C. immitis has 
been discovered in parts of Baja California (Baptista-rosas,  Raúl C, Jovani Catalán-
dibene
,  
Adriana L. Romero-olivares, Alejandro Hinojosa, Tereza Cavazos, and Meritxell 
Riquelme).  C. immitis and C. posadasii are estimated to be 97% identical indicating they 
are highly syntenic (Fisher MC, GL Koenig, TJ White, and JW Taylor). 
1.2   Clinical Symptoms 
Coccidioidomycosis is typically a respiratory illness acquired through inhalation of 
airborne arthroconidia, or spores, found in soil.  Coccidioidomycosis is not contagious 
between person-to-person as spore inhalation is the known route of transmission. In one 
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rare occasion, records indicate the transmission of coccidioidomycosis from a cat bite to a 
human leading to a cutaneous lesion (Gaidici, Adriana, and Michael Saubolle).  
Approximately 60% of humans who become infected with C. immitis or C. posadasii 
remain clinically asymptomatic (Blair, Janis, Anita Mayer, Jeremiah Curriera, Julia Files, 
Qing Wu).  Those who become symptomatic may have symptoms anywhere from one to 
four weeks after infection resembling tuberculosis or histoplasmosis; including a dry 
cough, fever, lack of energy and appetite. Other species have been recorded to be 
susceptible to coccidioidomycosis include dogs, llamas, non-human primates, cats, 
horses, wild mammals, and snakes.  Symptoms are generally similar to human mycosis 
with additional, yet less common, symptoms such as seizures or long bone pain and 
lesions (Centers for Disease Control and Prevention). 
Disseminated Coccidioidomycosis occurs in approximately 5% of patients which initially 
presents with an acute infection (Drake, Kevin, and Richard Adam).  Disseminated 
Coccidioidomycosis generally begins in the lungs with a granulomatous presentation (Fig 
2).  Although Valley Fever, also called Desert Fever, California Fever, and San Joaquin 
Valley Fever was named because of the high incidence of infection in Central California, 
the Phoenix and Tucson areas have been the epicenter for VF for many years. An 
estimated 150,000 human cases are diagnosed annually with 60% of those infections 
occurring in the people of the Maricopa, Pima, and Pinal counties of Arizona 
(Sunenshine RH, S Anderson, L Erhart, A Vossbrink, PC Kelly, D Engelthaler, and K 
Komatsu).   
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1.3  Current Diagnosis of Coccidioidomycosis 
Upon inhalation the arthrospore settles in the lungs and develops into a spherule 
containing many endospores.  Arthroconidia are phagocytized by host mononuclear cells 
followed by a respiratory burst.  This respiratory burst may initiate the maturation of the 
arthroconidia into endosporulating spherules (Galgiani, J. N., R. Hayden, and C. M. 
Payne ).  This response would promote mononuclear cells to proliferate further.  
Diagnosis of VF is challenging due to the reliance of laboratory serology and the 
necessary presence of coccidioidal antibodies in the host.  To avoid false negatives the 
serological test methods must be so fine tuned that a vast plethora of coccidioides 
immunogens are present.  Current serological testing includes tube precipitation (TP) 
assay, a complement fixation (CF) assay, and immunodiffusion assays.  All of these 
assays rely on the detection of an antigen-antibody complex.  The TP assay detects IgM 
responses to Beta-glucosidase which are seen at approximately week 2 of primary 
infection (Pappagianis D) but drops dramatically around month 2 of infection. The CF 
assay detects IgG to chitinase which fixes complement.  IgG is typically detected around 
month 2 post infection and fully around month 9 (Pappagianis D).  Titers of antibodies, 
both IgM and IgG, can be obtained via an enzyme immunoassay (EIA) which is highly 
sensitive but not as specific as the TP and CF assays.  Again, these serological assays 
depend on detecting antigen-antibody complexes with antibody titers being proportional 
to severity of disease.  It is important to note that not all patients infected with 
coccidioides may have proper functioning humoral immune responses (Blair, Janis, Anita 
Mayer, Jeremiah Curriera, Julia Files, Qing Wu). 
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1.4  Plasma as a diagnostic tool 
Blood consists of approximately 22% solids and 78% water (Farley, Alistair, Charles 
Hendry, and Ella McLafferty).  Blood consists of components such as red blood cells, 
white blood cells, platelets, with the plasma portion consisting of highly abundant 
proteins such as albumin, transferrin, macroblobulin, immunoglobulin, as well as other 
biologic molecules that are present down to femtomolar concentrations.   Plasma is a rich 
vault of proteins and is an ideal source to detect biomarkers since it flows throughout 
every organ of the body (Zheng X, H Baker, and WS Hancock).  Both host and pathogen 
proteins may be broken down by proteases leaving peptide fragments behind.  Although 
these peptides can be as small as ~700 Da and may be in the femtomolar range chemists 
may use liquid chromatography–mass spectrometry (LC-MS/MS) as a useful tool in 
detecting these peptides (Cutillas, PR). 
LC-MS is one of the most powerful tools to an analytical chemist.  A multiple component 
mixture, such as plasma, is ionized after separation of the liquid into components, usually 
based on charge or hydrophobicity.  These ions are electrostatically extracted onto a 
capillary tube which are analyzed by mass.  Furthermore, an accelerated voltage is 
applied and once the acquired energy exceeds the ionization potential of the molecule the 
energy is dispersed though the molecule.  When the dissociation energy from the 
molecule is reached fragmentation occurs.  The fragmentation data can be analyzed for 
each amino acid allowing the amino acid sequence to be determined. 
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1.5  Peptide to Parent Protein 
Peptide sequences are useful in that they can be traced back to the parent protein or 
transcript using such bioinformatic tools as the “Basic Local Alignment Search Tool” 
(BLAST) and other databases such as those provided by the Broad Institute.  
Bioinformatics allows a peptide to be aligned with a suspected transcript or parent 
protein.  This information can be taken to the biology laboratory where wet lab 
experiments such as PCR and DNA gel electrophoresis can be performed to verify its 
presence in the genome. 
The uses of a Western Blot along with monoclonal antibodies are paramount laboratory 
tools when searching for a parent protein.  Compared to polyclonal antibodies, 
monoclonal antibodies are more specific as they are derived from a single B cell.  A 
mammalian splenocyte is fused with a myeloma cell creating a hybridoma.  This 
hybridoma produces one identical antibody of a single specificity.  For this reason, the 
use of the MABs is a common tool to probe for a parent protein to verify translation. 
1.6 Hypothesis 
Diagnostic serology-detection of an antibody response is problematic for patients and 
their doctors, especially those who are immunocompromised.  Patient plasma can be used 
to detect peptides secreted or released by the pathogen which can be traced back to either 
the host or pathogen genome.  These peptides can be used as biomarkers to show the 
presence of an active infection in patients with Coccidioidomycosis.   
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Figure 1  Life Cycle of Coccidioides:  Life cycle of C. posadasii and C. immitis 
(DiCaudo, 2006) 
 
 
Figure 2  Patient with Lung Granuloma :  Patient with Coccidioidomycosis lung 
granuloma (Burhan, 2011) 
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CHAPTER 2 
EXPERIMENTAL: METHODS AND MATERIALS  
2.1  ELISA, T27K, and Plasma 
The antigen preparations T27K and Crushed Spherule Supernatant (CSS) were obtained 
through two different laboratories using two different techniques.  To ensure antigenicity, 
an ELISA was performed to determine if they were immunogenic to patients with active 
coccidioidomycosis.  The importance of knowing if there was antigenicity was because 
these antigen preparations would be paramount as they would be used in future 
experiments mentioned in this thesis. 
Peripheral blood was obtained from both canine donors, graciously provided by 
Scottsdale Ranch Animal Hospital, and human donors within 8 weeks of diagnosis with 
coccidioidomycosis.  Some of these patients were taking anti-fungal medication.  
Peripheral blood was also obtained from healthy donors, both canine and human, from 
the endemic area in Phoenix, Arizona, who had never been diagnosed with 
coccidioidomycosis.  Plasma was harvested from separation of peripheral blood on a 
Ficoll gradient.  One antigen preparation, T27K, is a thimerosal-inactivated spherule 
lysate that is prepared from mature endosporulating spherules of C. posadasii strain 
Silviera and centrifuged at 27,000 rpm.  The supernatant is retrieved and thus called 
T27K. (Johnson,  Susan M, KA Simmons, and Pappagianis).   T27K was graciously 
provided by Dr. Susan Johnson, of UC Davis Medical School.  
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Preparing ELISA plate: 
An Enzyme Linked Immuno Assay (ELISA) 96 well plate was coated with either 100uL 
of 10ug/mL of T27K or 100uL of 2ug/mL of Bovine Serum Albumin (- control) which 
was diluted in coating buffer (Na2CO3 +NaHCO3).  The 96 well plates were incubated for 
1 hour at 37C.  The plates were washed 3 times with 200uL of 0.05%tween in 1XPBS.  
The plates were dried by manual blotting against a paper towel.  200uL of blocking agent 
consisting of 1%BSA in 1XPBS was added to the wells in the washed plate and allowed 
to incubate for 2 hours at 37C.  The plates were washed 3 times with 200uL of 0.05% 
tween in 1XPBS.  The plates were dried by manual blotting against a paper towel.   
  
 
Preparing plasma for introduction to the ELISA plate: 
Canine Plasma – Canine plasma was diluted at 1:1000 with 1XPBS and introduced into 
each of the coated 96 well plates.  2-fold serial dilutions were made. 
Human Plasma – Human plasma was diluted at 1:500 with 1XPBS and introduced into 
each of the coated 96 well plates.   2-fold serial dilutions were made. 
The ELISA plate was incubated for 1 hour at 37C. 
The ELISA plates were washed 3 times with 200uL of 0.05% tween-20 in 1XPBS.  The 
plates were dried by manual blotting against a paper towel after each wash.  100uL of 
secondary antibody was added to every well in the plate at a dilution of 1:5000 for each 
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species.  The secondary antibody for the ELISA plates with canine plasma consisted of 
goat-anti-canine horse radish peroxidase in 1%BSA in 1XPBS.  The secondary antibody 
for the ELISA plates with canine plasma consisted of goat-anti-human horse radish 
peroxidase in 1%BSA in 1XPBS.  This was incubated for 1 hour at 37C.  The wells in the 
plates were washed 7 times with 200uL of 0.05%tween in 1XPBS.  The plates were dried 
by manual blotting against a paper towel after each wash. 
100uL of TMB was added to each well and allowed to develop at room temperature for 
25 minutes.  50uL of 2N H2SO4 was used to stop the reaction.  The ELISA plates were 
then read on a plate reader with Softmax Pro 5 software and optical density (OD) values 
were evaluated. 
 
2.2  Liquid Chromatography-Mass Spectrometry (LC-MS) 
Separation and Analysis of Peptides 
Plasma samples from patients with serologically confirmed coccidioidomycosis and 
control subjects were filtered through Centricon (Millipore) centrifugal filters with 
MWCO of 3kDa. The filtrates were either analyzed immediately or transferred into 
siliconized tubes and stored at -20 °C until analysis. Each sample was analyzed by adding 
0.1 mL of 3kDa filtrate to 0.9 mL of 0.1% TFA solution with pH adjusted to 2.5. Diluted 
samples were then desalted on Bond Elut-C18 EWP solid phase extraction (SPE) 
columns (Varian, Inc.) as follows. Columns were wet with 1 mL of 100% acetonitrile, 
washed with 1 mL of 0.1% TFA solution before loading diluted samples. Columns were 
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washed with 3% acetonitrile in 0.1% TFA. Peptides that were trapped on the column 
were eluted with 1 mL of 50% acetonitrile in 0.1% TFA solution and dried on Speedvac. 
The dried samples were reconstituted in 15 µl of 3% acetonitrile in 0.1% FA of which 12 
µl were injected on C18 PicoFrit column (New Objective) on a Thermo Finnigan 
Surveyor HPLC system (Thermo Scientific). Peptides were resolved on the PicoFrit 
column with elution gradient running from 5 to 50% in 30 min and 50-100% in 10 min 
with mobile phase B (90% ACN, 0.1% formic acid in LCMS grade water) versus mobile 
phase A (3% ACN, 0.1% formic acid in LC-MS water) at a flow rate of 0.6 µL/min. The 
eluted gradient was analyzed on-line with nanoelectrospray ionization (nano-ESI) linear 
ion trap mass spectrometer (LTQ, Thermo Scientific) in the positive ion mode. The high 
voltage capillary was set at 2.60 kV. Mass spectrometer (MS) full scans were acquired 
from 350 to 1500 m/z in data-dependent mode. Ten most abundant ion peaks above the 
background in each mass spectrum were selected as precursor ions for tandem mass 
spectrometry (MS/MS) using collision-activated dissociation (CAD). MS/MS scan of the 
same ion was not allowed in more than two MS spectra that were obtained within a 
period of 1 min.  
 
Synthetic Peptides  
Because of the relatively large precursor mass tolerance (1.5 Da) used in the database 
search, PGLDSKSLACTFSQV peptide was chemically synthesized and run on the LC-
MS/MS under the same conditions as described above for the natural peptide to make 
sure the retention time and spectra matched. Peptides were synthesized at the proteomics 
core facility at Arizona State University on a Milligen 9050 peptide synthesizer 
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(Millipore, Bedford, MA). Stable heavy isotope labeled peptide 
PGL*DSKSLACTFSQV, which had all six carbon-12 and nitrogen-14 in Leu12 
(C6H13NO2) substituted with carbon-13 and nitrogen-15, respectively, was synthesized 
by Anaspec, Inc. (San Jose, CA). Mass of the peptide was determined by amino acid 
analysis. After HPLC purification, the purity of all synthetic peptides was estimated to be 
greater than 95%. Mass spectrometric analysis was used to confirm amino acid 
composition of peptides. 
 
3.3  Transcriptomics 
 
cDNA Sequence Analysis 
cDNA sequence analysis was performed using total mRNA from C. posadasii RMSCC 
3488.  SuperScript® III First-Strand Synthesis System for RT-PCR (Invitrogen) was used 
to reverse-transcribe mRNA to cDNA.  Genomic DNA from C. posadasii was used as a 
positive control to determine if genomic DNA contamination was present in the total 
RNA preparation.  Primers (Forward:  GTCTATGCGTGTCCCCACTT ; Reverse:  
CGTCGAAGATGCAAGAGTGA) for the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) specific for C. posadasii were developed and used 
to confirm the absence of genomic DNA. PCR primers within annotated exons flanking 
the PGLD peptide (Forward:  GGTAATCCGGAAGCTCAACC; Reverse: 
GTCGATGTCCTGGACGAAGT) were synthesized based on the annotation of the 
predicted protein C. posadasii RMSCC 3488: CPAG_04641 (Broad Institute). cDNA was 
amplified by PCR using 5’ and 3’ primers flanking the PGLD peptide and 
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electrophoresed on a 1% agarose gel.  DNA bands were excised and gel purified with 
GeneJET® Gel Extraction Kit (Thermo Scientific). 
The extracted DNA was ligated and cloned into T-vector using Life Sciences TA Cloning 
Kit.  Plasmid DNAs were purified using GeneJet plasmid miniprep kit (Thermo 
Scientific).  Inserts were sequenced by the ASU DNA sequencing facility and analyzed 
with DNA Baser.   The DNA sequence was then translated and aligned with the Broad 
Institute sequence using ClustalW2. 
In addition to comparing the genomic amplified sequence with the cDNA-amplified 
sequence a “primer walk” was performed to evaluate the possibility that exon 1 (5’ end) 
may actually be annotated incorrectly.  To perform the primer walk  cDNA was obtained 
from total mRNA from C. posadasii RMSCC 3488.  SuperScript® III First-Strand 
Synthesis System for RT-PCR (Invitrogen) was used to reverse-transcribe mRNA to 
cDNA.  The predicted protein C. posadasii RMSCC 3488: CPAG_04641 (Broad 
Institute) annotation of  the genomic sequence was used to develop primers spanning the 
1KB flanking genomic region of 5’ and 3’ ends.  The primer walk on the 3’ end lead to 
no cDNA amplification therefore primers are not listed.  The primers for the 5’ end of the 
1KB genomic flanking region are as follows:  1)  “889” - GGT GCA AAG GTG TAA 
CGA TTC, 2) “810” -  AGA TCT CGT GGG ATC TCC TA, 3) “640” -  CAG ATG 
ATC GAG AGG TGG AG, 4) “460” -   ACA TCG CCA GCT GAT TCT AT,  5) “280” -  
CAA GTC TCC CTT TCC CGG AT, and 6) “192” -  TAA ACC GTG AAA TAG GGT 
TGA AGA GG.  The PCR primer within annotated exons flanking the PGLD peptide was 
used for the reverse (Reverse: GTCGATGTCCTGGACGAAGT) and were synthesized 
based on the annotation of the predicted protein C. posadasii RMSCC 3488: 
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CPAG_04641 (Broad Institute). cDNA was amplified by PCR using 5’ and 3’ primers 
flanking the PGLD peptide and electrophoresed on a 1% agarose gel.  DNA bands were 
excised and gel purified with GeneJET® Gel Extraction Kit (Thermo Scientific).  
Extracted DNA was sequenced by the ASU DNA sequencing facility and analyzed with 
DNA Baser.   The DNA sequence was then translated and aligned with the Broad 
Institute sequence using ClustalW2. 
 
2.4  Peptide to Parent Protein 
Monoclonal Antibody Generation 
The PGLDSKSLACTFSQV peptide was synthesized by the proteomics facility at ASU 
and coupled to KLH (Thermo/Pierce, Rockford, IL).  50ug of peptide-KLH was used to 
immunize mice in Freund’s complete adjuvant (Thermo/Pierce, Rockford, IL), followed 
by boosting with the peptide-KLH conjugate in Freund’s incomplete adjuvant.  When 
titers were greater than 12,800 against the peptide, mice were euthanized and splenocytes 
harvested.  Splenocytes were then fused with P3 murine myeloma cells, plated into 96-
well flat-bottom plates and incubated in 10HY media containing hypoxanthine 
aminopterin and thymidine for 2 weeks.  Hybridoma supernatants were tested in a 
peptide-based ELISA for the ability to secrete antibodies specific for PGLD peptide 
against PGLDSKSLACTFSQV (PGLD) peptide and a control peptide.  Positive 
hybridomas from the peptide screening were graciously cultured by the laboratory of 
David Azorza at TD2, Scottsdale, AZ,  and subcloned by limited dilution (one cell per 
15 
well) at least three times to ensure monoclonality.   Anti-PGLD hybridomas were mass 
cultured and purified on Protein A/G (Thermo/Pierce, Rockford, IL). 
 
 
Western blot Analysis 
Crushed Spherule Supernatant (CSS) is a supernatant derived from C. posadasii strain 
Silviera spherules were obtained from culture after 96 hours of incubation.  The spherules 
are introduced to glass beads and vortexed at 3000rpm/3min.  This is then centrifuged to 
pellet the cracked spherules and the supernatant is retrieved.  T27K and CSS, generously 
provided by Dr. John Galgiani at the University of Arizona, were subjected to SDS-Page 
at 30ug per lane on a 12% Tris-tricine gel.  Proteins were transferred to a PVDF 
membrane and probed with anti-PGLD monoclonal antibody (Mab).  Goat anti-mouse 
IgG-alkaline phosphatase (Thermo Scientific) was used to detect anti-PGLD Mab.  Blots 
were developed with NBT/BCIP (Thermo Scientific) for 45 minutes. The molecular 
weight marker used was Invitrogen See Blue® Pre-Stained Standard. 
To confirm specificity of the anti-PGLD Mab, an inhibition assay was performed by pre-
incubating 70uM of PGLD peptide with anti-PGLD Mab prior to adding the primary 
antibody Mab-peptide mixture to the PVDF membrane.  Goat anti-mouse IgG-alkaline 
phosphatase (Thermo Scientific) was used to detect anti-PGLD Mab.  Blots were 
developed with NBT/BCIP (Thermo Scientific) for 45 minutes. The molecular weight 
marker used was Invitrogen See Blue® Pre-Stained Standard. 
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N-linked Deglycosylation of T27K 
T27K was subjected to N-linked deglycosylation using the New England Biolabs®Inc. 
PNGase-F Kit™.  20ug of T27K was combined with 1ul of 10X Glycoprotein Denaturing 
Buffer.  The T27K was then heated at 100°C for 10 minutes in a thermocycler.  2uL of 
10X G7 Reaction Buffer, 2 µl of 10% NP-40, H20 and  2 μl of PNGase F were added to 
the T27K mixture and then incubated at 37°C for 1 hour. 
Untreated T27K along with PNGase-F treated T27K were subjected to SDS-Page at 30ug 
per lane on a 12% Tris-tricine gel.  Proteins were transferred to a PVDF membrane and 
probed with anti-PGLD monoclonal antibody (Mab).  Goat anti-mouse IgG-alkaline 
phosphatase (Thermo Scientific) was used to detect anti-PGLD Mab.  Blots were 
developed with NBT/BCIP (Thermo Scientific) for 45 minutes. The molecular weight 
marker used was Invitrogen See Blue® Pre-Stained Standard. 
To confirm specificity of the anti-PGLD Mab, an inhibition assay was performed by pre-
incubating 70uM of PGLD peptide with anti-PGLD Mab prior to adding the primary 
antibody Mab-peptide mixture to the PVDF membrane.  Goat anti-mouse IgG-alkaline 
phosphatase (Thermo Scientific) was used to detect anti-PGLD Mab.   
An additional inhibition assay was performed to also confirm specificity of the anti-
PGLD Mab and to also discount an unknown band at 35kD by pre-incubating 2ug/mL of 
PNGase-F with goat anti-mouse IgG-alkaline phosphatase (Thermo Scientific).  This was 
done by adding the goat-anti-mouse/PNGase-F  mixture to the PVDF membrane.  All 
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blots were developed with NBT/BCIP (Thermo Scientific) for 45 minutes. The molecular 
weight marker used was Invitrogen See Blue® Pre-Stained Standard.   
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CHAPTER 3 
RESULTS AND INTERPRETATION 
 
 
3.1 ELISA, T27K, CSS, and Plasma 
 
Canine Serology 
Canine serology commercial lab results were graciously provided by Scottsdale Ranch 
Animal Hospital (SRAH) as IgM and IgG titers.   These results were compared to those 
obtained from the ELISA assay performed using T27K.  (See Table 1)  As seen in the 
comparison between the positive canine laboratory results versus the T27K ELISA 
results, results would suggest that there are immunogenic and antigenic properties to the 
antigen prep T27K.   
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Patient Plasma Date Drawn Commercial Lab results 
T27K ELISA 
Results 
Kowboy (- control) 9-Oct (-) (-) 
Bandit Roberts 10-Jun (-) (-) 
Bart Brown 10-Mar (+) (+) 
Bo Czajka 10-Jun (-) (-) 
Bo Czajka 10-Sep (-) (-) 
Brutis Brodt 10-May (+) (+) 
Chance Benwell 9-Dec (-) (+) 
Chance Benwell 10-Sep (-) (-) 
Chippers Reagan 9-Oct (+) (+) 
Chippers Reagan 10-Mar (+) (+) 
Chippers Reagan 10-Jul (+) (+) 
Cooper Pasque 9-Dec (-) (+) 
Corky Hice 10-Feb (-) (-) 
Daisy Coakley 10-Jun (-) (-) 
Daisy Coakley 10-Sep (-) (-) 
Gretta Sinski 10-Feb (-) (-) 
Jazz Karpinski 10-May (-) (-) 
Jazz Leonow 10-Jan (-) (-) 
Lexie Gross 10-May (+) (+) 
Lexie Gross 10-Aug (+) (+) 
Masie Martinson 10-Jan (-) (+) 
Maya Callahan 10-Feb (+) (+) 
Motion Rostan 10-Sep (-) (-) 
Moxie Goodman 10-Mar (-) (-) 
Reggie Bartley 9-Dec (-) (-) 
Reggie Bartley 10-Sep (-) (-) 
Sophie Greer 9-Oct (-) (-) 
Wynni Marchetta 9-Dec (-) (+) 
Wynni Marchetta 10-Oct (+) (+) 
 
 
Table 1   Canine Coccidioidomycosis ELISA Results:  Commercial laboratory tests 
compared to T27K ELISA results. 9 canines tested (+) via the commercial veterinary 
diagnostic lab.  13 canines tested (+) via the ELISA using T27K as the antigen prep.  (For 
purposes of consistency, positive results were based off of 3 known VF healthy non-
immune canines with OD readings lower than 0.250.) 
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Interestingly, canine patient, Roxie Rowe, was serologically tested for 
Coccidioidomycosis with a commercially available diagnostic test when she presented 
with a skin lesion in August 2009.  As seen in Table 2, Roxie was serologically negative 
for Coccidioidomycosis yet a skin scrape culture proved a positive result for a 
coccidioidal skin lesion. In October 2010 Roxie tested positive via a commercial 
serological test for Coccidioidomycosis.  No plasma was available from either of these 
dates to test the plasma for antibody reactivity with T27K antigen prep.  In March and 
August of 2010 Roxie was again serologically tested via a commercial diagnostics lab 
which resulted in negative responses.  Whole blood was given to ASU and processed to 
obtain the plasma from these dates.  These plasma samples did show antibody reactivity 
to T27K when used in an ELISA assay.  Lastly, in December of 2010 Roxie continued to 
show negative results to the antigen preparation used in the commercially available 
diagnostic assay. 
 
 
 
 
 
 
Table 2  Roxie Rowe Coccidioidomycosis ELISA Results:  “Roxie” showing clinical 
symptoms of Valley fever in August 2009 with a positive Coccidioidomycosis skin 
scrape test yet commercial test show negative serological results.  Two months later 
commercial serology is positive with 2 negative results following.   According to T27K 
ELISA results “Roxie” continued to show an immunological response to T27K prep. (For 
purposes of consistency, positive results were based off of 3 known VF healthy non-
immune canines with OD readings lower than 0.250. 
 
 
Report Date 
Commercial 
Lab Results 
Commercial 
Lab Skin 
Scrape Results 
T27K ELISA 
Results 
8/26/2009 - + No plasma 
10/15/2009 + ND No plasma 
3/21/2010 - ND + 
8/27/2010 - ND + 
 12/02/2010 - ND No plasma 
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Human Results: 
Human serological assays were performed by a commercial laboratory and results were 
graciously provided by Janis Blair, MD, of Mayo Clinic along with whole blood from 
each patient or donor through IRB-approved protocols at Mayo Clinic and Arizona State 
University.   Human patients were grouped into 3 categories:  1 = actively infected with 
coccidioidomycosis; 2 = never diagnosed with coccidioidomycosis; and 3 = healthy 
immune to coccidioidomycosis. These results were compared to those obtained from the 
ELISA using CSS at ASU.  (See table 3)  As seen in the comparison between the positive 
laboratory results versus the CSS ELISA results, evidence would suggest that there are 
immunogenic and antigenic properties to the antigen prep CSS.   
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Sample 
Lab 
Results 
CSS 
ELISA 
Results Sample 
Lab 
Results 
CSS 
ELISA 
Results 
ND 82 N/A  - 1-0027  +  + 
ND 90 N/A  - 1-0028 Negative  + 
1-0001  +  + 1-0029 Negative  + 
1-0002 Negative  + 1-0030 Negative  + 
1-0003  +  + 1-0031  +  + 
1-0004  +  + 2-0001 N/A  + 
1-0005  +  + 2-0002 N/A  - 
1-0006  +  + 2-0003 N/A  - 
1-0007 N/A  + 2-0004 N/A  - 
1-0008  +  + 2-0005 N/A  - 
1-0009  +  + 2-0006 N/A  - 
1-0010 N/A  + 2-0007 N/A  - 
1-0011  +  + 2-0008 N/A  - 
1-0012  +  + 2-0009 N/A  - 
1-0013  +  + 2-0010 N/A  + 
1-0014  +  + 3-0001 N/A  + 
1-0015  +  + 3-0002 N/A  + 
1-0016 N/A  + 3-0003 N/A  + 
1-0017  +  + 3-0004 N/A  + 
1-0018 N/A  + 3-0005 N/A  - 
1-0020 N/A  + 3-0006 N/A  + 
1-0022 Negative  + 3-0007 N/A  + 
1-0023 Suspect  + 3-0008 N/A N/A 
1-0024 Suspect  + 3-0009 N/A  - 
1-0026  +  + 3-0010 N/A  + 
 
 
Table 3  Human Coccidioidomycosis ELISA Results:  Human Valley Fever patient 
results from a commercially available diagnostic assay were compared to results from an 
ELISA using Crushed Spherule Supernatant (CSS).   Group 1 patients were diagnosed 
with active Coccidioidomycosis, Group 2 donors were “healthy non-immune” donors, 
and Group 3 were “healthy immune” donors.  (For purposes of consistency positive 
results were based off of known VF healthy non-immune normal donors with OD 
readings lower than 0.340.) 
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All 26 Group 1 patients showed a positive result to the CSS based ELISA. 
In addition, 7 of the 10  patients in Group 3, those  who reported being  previously 
diagnosed with Valley Fever and were not considered as an active case, had a significant 
antibody response to the CSS antigen prep. 
Comparing the number of patients with active Coccidioidomycosis, whose plasma was 
evaluated using both the commercially available assay and the CSS ELISA, suggests that 
there are antigenic and immunogenic properties to the antigen preparation CSS. 
 
3.2 Liquid Chromatography-Mass Spectrometry (LC-MS) 
 
LC-MS/MS analysis was performed on the plasma peptidome from 20 patients with 
active coccidioidomycosis from the Phoenix area revealed over 100 peptides from C. 
posadasii translated database (data not shown).  A spectrum corresponding to one 
peptide, PGLDSKSLACTFSQV, was common to 15 of 20 patients with active disease, 
but was not present in any healthy control donors from the Phoenix endemic area (Table 
4).   
Plasma Sample from: Frequency of PGLD peptide in 
plasma 
Active Disease 15/20 
Non-immune healthy donor 0/13 
 
Table 4  Frequencies of PGLD Peptide in Human Plasma  
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Sample 
Commercial 
Lab Results 
LC/MS-
MS 
PGLD 
Detection 
1-0001  + - 
1-0002  - + 
1-0003  + - 
1-0004  +  + 
1-0005  + + 
1-0006  + - 
1-0007 
Not 
Available + 
1-0008  + + 
1-0009  + - 
1-0010 
Not 
Available + 
1-0011  + + 
1-0012  + - 
1-0013  + + 
1-0014  + + 
1-0015  + + 
1-0016 
Not 
Available + 
1-0017  + + 
1-0018 
Not 
Available + 
1-0020 
Not 
Available + 
1-0023 
Suspected 
Cocci + 
 
Table 5 Frequencies of PGLD peptide in plasma with Commercial lab results  
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The identity of the PGLD peptide was validated using LC-MS/MS methods. A PGLD 
peptide was chemically synthesized with a “heavy leucine” in the third position such that 
the mass of the synthetic peptide is 7 Daltons heavier than the natural plasma-derived 
peptide.  This peptide was then spiked into plasma from patients with active disease 
followed by LC-MS/MS.  Selective Reaction Monitoring (SRM) of the peptide ion 
fragmentation is shown in figure 3.  The top spectra show b and y ion fragmentation of 
heavy PGLD such that selected SRM peaks are 7 Daltons heavier than the identical b and 
y ion peaks in the natural peptide in the bottom spectra. 
 
 
Figure 3  Mass Spec Data of PGLD peptide:  Mass spectra of synthetic heavy PGLD 
peptide (top) compared to natural plasma-derived peptide from a human donor with 
active disease (bottom).  B-ions are colored and represent peptide fragmentation mass 
from the C-terminal end of the peptide at each peptide bond. For each labeled b-ion the 
top spectra shows a 7-Dalton difference in mass for each fragmentation.  
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3.3   PGLD RNA Analysis 
 
PGLDSKSLACTFSQV mapped back to the open reading frame of CPAG_04641.1-
predicted protein in the C. posadasii strain RMSCC 3488 genome by Broad Institute (See 
Figure 4).  This ORF is conserved throughout all C. posadasii strains, but is not annotated 
by Broad Institute as an ORF in C. immitis. 
 
Figure 4 PGLD Peptide Identified on Predicted Protein:  PGLD peptide maps to 
“CPAG_04641.1-predicted protein” on chromosome 2.  Arrow pointing to red line 
indicates location of peptide in CPAG_04641.1. DNA sequence chromatogram from PCR 
amplification of C. posadasii mRNA/cDNA shows the nucleotide and amino acid 
sequence of the region flanking and including PGLD peptide. 
 
Sequencing of a cDNA amplified from mRNA, with oligonucleotides flanking the 
predicted gene CPAG_04641.1 indicated that the intron predicted between exons 1 and 2, 
does not exist.  Because it was a possibility that the polyA mRNA was contaminated with 
genomic DNA, the presence of genomic DNA was tested for by amplifying the 
  5’ 3’ 
PGLDSKSLACTFSQV 
 
   Exon 1                     Intron              Exon 2 
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Coccidioides GAPDH gene with primers on adjacent exons using either coccidioidal 
cDNA or genomic DNA as template (figure 2).  The GAPDH genomic DNA PCR 
product is 272 bp, while the predicted cDNA product is 197 bp, lacking a 75 nt intron. As 
shown in figure 2, there was no evidence of amplification of the genomic DNA product 
in the cDNA lane for GAPDH indicating the mRNA used for cDNA preparation was not 
contaminated with genomic DNA.  Using the PGLD primers the same size amplicon is 
present in the genomic DNA and cDNA template lanes Fig 2, lanes 3 and 4), indicating 
that there is no intron in the CPAG_04641.1 transcript as annotated by Broad Institute 
(figure 5).  Sequence analysis confirms the identity of both genomic and cDNA PCR 
products. This strongly suggests that the predicted intron does not exist in this gene.  
Removal of the intron suggests that the ORF containing the PGLD peptide is 55 residues 
in length (figure 6). 
 
Figure 5  PCR Amplification of PGLD Transcript:  Amplification of PGLD in both 
Spherule cDNA and Mycelium cDNA 
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Primer Walking 
A primer walk ~1KB upstream of PGLD genomic region of the C. posadasii is shown in 
Figure 6.  Sequencing of the amplified cDNA with oligonucleotides flanking 1KB of the 
Broad Institute annotated genomic region of the 5’ end of the predicted gene 
CPAG_04641.1 indicated that there are 10 stop codons in this region and does not reflect 
the presence of start codons (Figure 7).  This further indicates that the actual size  of the 
transcript is not due to upstream transcription of the 5’ end but instead that there is no 
intron in the CPAG_04641.1 transcript as annotated (Broad Institute).  Sequence analysis 
confirms the identity of all cDNA PCR products in the primer walk to contain PGLD. 
This strongly suggests that the intron predicted by the Broad institute does not exist in 
this gene.   
 
 
Figure 6  Primer Walking of Genomic PGLD Region:  Primer Walking via PCR of 1kb 
genomic sequence on the 5’ end.  
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Figure7  Amino Acid Sequence from Primer Walk:  DNA and Amino Acid Sequence 
results of “Primer Walk” to determine possible alternative start codons.  Translation 
performed by ExPASy. 
 
 
 
3.3  Peptide to Parent Protein 
Characterization of anti-PGLD Monoclonal Antibodies (MAbs): 
 
Hybridoma supernatants from mice immunized with PGLD peptide that tested positive 
by peptide ELISA were re-tested in Western blotting against CSS and T27K. A 
hybridoma was identified that secretes anti-PGLD MAb and also recognizes a  ~16kDa 
protein in the T27K lysate, but does not bind to antigen in the CSS (Figure 8).  As proof 
that the antigen-PGLD Mab recognizes a coccidioidal protein containing the PGLD 
peptide sequence, an inhibition was performed using PGLD peptide of the MAb binding 
to the parent protein in the T27K by PGLD peptide, while a control peptide with a 
different sequence does not inhibit binding of anti-PGLD Mab (Figure 9).  
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Figure 8   Reactivity of anti-PGLD MAb with T27K.  Left blot:  (-) Control = No PGLD 
Mab with T27K antigen preparations (secondary  =  antibody only).  Right blot:  Anti-
PGLD Mab 5ug/mL with CSS and T27K antigen preparations.    
 
 
 
 
Figure 9  Reactivity of anti-PGLD MAb with T27K and Crushed Spherule Supernatant 
(CSS).  Left blot:  Anti-PGLD Mab (5ug/mL) was incubated with each blot containing 
lanes T27K and CSS antigen preparations.  Middle blot: Anti-PGLD Mab (5ug/mL) was 
pre-
with the blot. Right blot:  Same as middle blot, 
(VVAGLGRAVTRL).   
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Deglycosylation of T27K 
 
PGLD Mabs were used to probe for PGLD in Western blotting against T27K, both 
untreated and N-linked deglycosylation with PNGase-F.   A doublet band was seen 
around 16kDa and 13kDa in the T27K deglycosylated with PNGase-F (Figure 10).   As 
proof that the antigen-PGLD Mab recognizes a coccidioidal protein containing the PGLD 
peptide sequence in T27K, both untreated and deglycosylated, an inhibition was 
performed using PGLD peptide (Figure 11).   
An additional protein band was seen around 35kDa with deglycosylation of T27K.  The 
molecular weight of PNGase-F is 36kDa.  As proof that this band was not related to any 
coccidioidal protein an inhibition was performed to determine nonspecific binding of the 
secondary antibody vs. the anti-PGLD Mab to PNGase-F (Figure 12).   
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Figure 10  Reactivity of anti-PGLD Mab with T27K Deglycosylated:  Reactivity of anti-
PGLD MAb with T27K and T27K deglycosylated with PNGase-F.  Anti-PGLD Mab 
(5ug/mL) was incubated with blot containing lanes T27K and T27K deglycosylated 
preparations.   
 
 
 
Figure 11 Reactivity of anti-PGLD Mab with T27K and PNGase-F:   Reactivity of anti-
PGLD MAb with T27K, T27K after being deglycosylated with PNGase-F, and PNGase-
F alone.   Left blot:  Anti-PGLD Mab (5ug/mL) was incubated with each blot containing 
lanes T27K, T27K after being deglycosylated with PNGase-F, and PNGase-F alone.  
Right blot: Anti-PGLD Mab (5ug/mL) was pre-
30 minutes, then the mixture was incubated with the blot.  
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Figure 12  Reactivity of Secondary Ab and PNGase-F :  Reactivity of anti-PGLD MAb 
and Goat-anti-mouse Ab with PGNase-F.  Left blot:  Anti-PGLD Mab (5ug/mL) was 
incubated with each blot containing 2 lanes of PNGase-F.  Middle blot: Negative control 
= secondary antibody was incubated with each blot containing 2 lanes of PNGase-F.  
Right blot:  Secondary antibody (1ug/mL) was pre-incubated with 2ug/mL of   PGNase-F 
for 30 minutes, then the mixture was incubated with the blot. 
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CHAPTER 4 
SUMMARY AND CONCLUSIONS  
4.1 Summary and Discussion 
Coccidioidomycosis is caused by the soil dwelling dimorphic fungus C. immitis and C. 
posadasii. Endemic areas in the United States include California, Arizona, and Texas.  
The route of exposure is through inhalation of the arthroconidia, or spores, which are 
found in soil.  Approximately 40% of those who become infected Coccidioides will 
become symptomatic (Sunenshine RH, S Anderson, L Erhart, A Vossbrink, PC Kelly, D 
Engelthaler, and K Komatsu).  Symptoms include those similar tuberculosis including 
dry cough, fever, lack of energy, and appetite (Smith, 1955).   Disseminated 
Coccidioidomycosis occurs in approximately 5% of those infected (Sunenshine RH, S 
Anderson, L Erhart, A Vossbrink, PC Kelly, D Engelthaler, and K Komatsu).  Current 
diagnostic tests include serological tests, cultures, and sputum smears.  For those with a 
compromised immune system these diagnostic tests may show false negative results since 
serological testing is dependent on antigen-antibody reactivity.  Even in otherwise 
healthy individuals with no known immune suppression, immune responses to the fungus 
may be delayed or aberrant.   
Plasma is an excellent tool in diagnostics as it contains valuable biomarkers both from the 
host and the pathogen. Plasma has been used to detect biomarkers in multiple different 
diseases which has enabled development of new and innovative ways to detect disease 
(Zheng X, H Baker, and WS Hancock).   Disadvantages of using plasma to detect 
biomarkers include the dynamic qualitative and quantitative range of proteins. Great care 
must be taken in sample preparation due to the interference of intrinsic plasma proteins 
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like albumin and immunoglobulins (Heide, K., H Haupt, and H.G. Schwick).  
Bioinformatics must be utilized to eliminate host peptides prior to determining useful 
biomarkers.  This thesis represents very early attempts to detect and validate coccidioidal 
antigens as biomarkers in plasma for definitive diagnosis of valley fever. 
Commercial lab diagnostic tests results were used to evaluate immunogenicity of T27k 
and CSS via ELISA.   This was done to provide evidence of the antigenicity and 
immunogenicity of the antigen preparations as they would be used in future experiments.  
All of the human plasma samples with an active case of coccidoidomycosis indicated a 
positive signal to CSS.  In the canine ELISA using T27K antigen preparation 15 out of 
the 20 samples reflected a positive signal.  Without delving deeper into antibody cross 
reactivity, these results would indicate that T27K and CSS are antigenic to those with 
active cases of coccidoidomycosis and these preparations would be adequate for further 
investigations.  Current commercially available diagnostic assays may present false 
negative results.  Since the objective was not to prove this statement it cannot be 
confirmed by the results presented.  In fact, the reason for the uncertainty lies in the 
unknown composition of the antigen preparations T27K and CSS.  A more thorough 
examination of the immunogenic factors in T27K and CSS would need to be performed.  
The fact that CSS and T27k have shown to be immunogenic by use of the ELISA makes 
them an ideal candidate for use for searching for parent proteins.   
An alternate way to detect infection is to detect components (peptides, proteins, nucleic 
acid, carbohydrates, etc…) of the infectious agent itself.  Screening of plasma was done 
by filtering with a 3KDa filter and analyzed with LC-MS/MS a 15-mer peptide 
(PGLDSKSLACTFSQV ) was found in 15 of 20 patients with active 
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Coccidioidomycosis.   The fact that PGLD was not found in 5 of the 20 patients cannot 
adequately be explained since the plasma samples were subjected only once LC-MS/MS 
and no validation of the results were performed due to lack of project funding.  
Additional validation, running the samples again using LC-MS/MS, would give a better 
level of confidence of the absence of PGLD.  As mentioned, PGLDSKSLACTFSQV  
mapped  back to the CPAG_04641.1-predicted protein in the C. posadasii strain Silviera 
RMSCC 3488.  The fact that PGLD was only amplified in C. posadasii cannot be 
explained nor can it definitively be stated that it only exists in C. posadasii in this thesis.  
As mentioned previously, the two species are said to be 97% genetically identical so it 
should not be assumed that C. immitis contains the gene containing the PGLD ORF.  In 
fact, The Broad Institute database indicates that C. posadasii is the only one of the two 
species containing the ORF. Due to lack of funding, RNA from C. immitis was not able 
to be obtained nor purchased for any of these experiments and, therefore, should be 
further investigated. The absence of PGLD in C. immitis relies solely on bioinformatics 
and remains defined as absent by The Broad Institute database.  On the other hand, the 
presence of the gene containing the PGLD ORF has been verified in C. posadasii by 
experimentation as noted in this thesis. 
PCR amplification indicated that the intron predicted between exons 1 and 2 does not 
exist since the predicted size is 161 bp and the amplified size was 340bp.  Before making 
the assumption that the Broad Institute annotation was incorrect, and to ensure this was 
not due to genomic contamination, GAPDH was used as a housekeeping gene which 
validated the cDNA did not contain any genomic DNA.  To further evaluate the 
discrepancy in the size of the nucleotide sequence a primer walk was performed.  The 
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primer walk for the 3’ end yielded no amplification.  The lack of amplification indicates 
that the transcript of  CPAG_04641.1-predicted protein ends at the annotated region and 
that no adjacent gene exists within 1KB downstream.  The primer walk for the 5’ end 
yielded amplification in the 1KB annotated genomic region flanking the 5’ end.  
Although it does not provide an explanation for the increase in size for the product 
amplified it does indicate that there is an adjacent transcript upstream within 1KB of the 
PGLD ORF.  After further investigation using Broad Institute BLAST this region is 
actually amplification of the 3’ end of an upstream gene CPAG_04640.  Although highly 
unlikely, the upstream gene CPAG_04640 may be fused to the gene containing the PGLD 
ORF.  On the other hand, due to the presence of multiple stop codons in this region it was 
hypothesized that this sequence was not associated with the predicted protein 
CPAG_04641.1. 
A monoclonal antibody to the 15-mer peptide PGLDSKSLACTFSQV was generated 
from splenocytes from Balb/C mice inoculated with the peptide.  Hybridomas were 
generated from the monoclonal antibodies and used to probe in Western blotting.  The 
results of the Western blotting show the PGLD Mab reacted with a protein approximately 
16KDa in the T27K antigen preparation but not in the CSS.  To verify for antibody 
specificity an inhibition assay was performed using the PGLD peptide as the inhibitor 
and VVAG peptide as the control peptide.  Results indicate that the PGLD Mabs were 
inhibited by the PGLD peptide but not the VVAG peptide.  Unless antibody cross 
reactivity is unknowingly involved, the parent protein for the PGLD peptide is ~16kDa. 
Interestingly, use of the CSS did not yield any antibody-antigen reactivity when probing 
with the PGLD Mab.  Although the Silviera strain from the two antigen preps T27K and 
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CSS is the same, the culture method is different.  Possible reasons for PGLD Mab 
reactivity with T27K and not CSS could be that the fungus used in T27K is more closely 
related to that which infects humans.  Another possible reason could be due to the method 
and time at which the spherules are retrieved.  The fact that the T27K antigen preparation 
is prepared from endosporulating spherules may play a role.  In addition, although the 
strains are identical, genetic variation between the two preparations could be possible.  
None of these possible explanations could be validated at the time and deserve future 
investigation.  
A primary question raised by this study is the fact that the PGLD Mabs reacted with a 
protein approximately 16KDa.  According to the results of the sequence analysis 
performed using the RNA from the PGLD regions the protein should be approximately 
6KDa.  Since transcripts are all subject to post transcriptional modifications (PTM)  the 
PTM glycosylation was evaluated.  Glycosylation can be N-linked (linked to an 
asparagine) or O-linked (linked to serine or threonine).  The gene which was amplified 
has the possibility of (11) O-linked glycosylation sites and (3) N-linked glycosylation 
sites.  To test this hypothesis the use of an N-linked deglycosylation technique using 
PNGase-F was used in attempt to remove any N-linked sugars.  Deglycosylation of O-
linked sugars could not be performed at the time of this study due to lack of funding.  
After N-linked deglycosylation of T27K the Western blotting shows PGLD Mab 
reactivity with both a 16KDa protein and a 13KDa protein.  Since it is well known that 
fungi heavily glycosylate their proteins, the increase in the expected size of the protein 
could be due to glycosylation.   The fact that there was only a slight decrease in mass 
could be due to only performing N-linked deglycosylation.  An experiment using an O-
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link deglycosidase would have been much more beneficial as the protein has many more 
possible O-linked sites.  Since O-linked deglycosylation was not performed to confirm if 
the higher molecular weight was due to heavy glycosylation of the protein, it cannot be 
confidently concluded that the size difference is due completely to glycosylation.    
Plasma has been shown to be a valuable vault for biomarkers.  A 15-mer peptide mapped 
back to a predicted protein in the coccidioidal proteome.  The transcript containing the 
peptide was amplified and showed that the annotated intron does not exist.  This in itself 
shows that bioinformatic modeling of proteins may be erroneous and should 
appropriately be verified by experimentation.   
This discovery along with the bench work confirmation indicates that a coccidioidal 
peptide has been detected by LC-MS/MS in patients with an active case of disseminated 
coccidioidomycosis.  Since the Broad Institute BLAST indicates that the peptide maps 
back to a parent protein LC-MS/MS may be used as a valuable clinical tool in diagnosing 
pathogen presence long before an immune system response. 
A more specific and selective diagnostic tool must be discovered for patients, especially 
those who are immunocompromised.  Patient plasma can be used to detect peptides 
present in the host which can be mapped back to either the host or pathogen peptidome.  
These peptides, such as the 15-mer peptide P G L D S K S L A C T F S Q V reviewed in 
this thesis,  can be used as biomarkers to show the presence of an active infection in 
patients with Coccidioidomycosis.  
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4. 2 Future Studies 
To help define the PGLD parent protein and its function further studies should be 
performed.   Since the fungal pathogen is known to be highly glycosylated it would be 
beneficial to perform O-linked deglycosylation and continue with a Western Blot.  This 
would affirm or negate the hypothesis that  the higher molecular weight is primarily due 
to glycosylation.  In addition, further investigation should be done to verify  the absence  
of CPAG_04641.1-predicted protein in C. immitis to determine if it is specific for C. 
posadasii.  
Knowing functionality of the protein is essential in future investigations.  Purification 
should be done by passing T27K through a PGLD Mab immunoprecipitation column.  
Purification and isolation would allow for  LC-MS/MS on the parent protein giving a  
better annotation the amino acid sequence.  Once purified the parent protein may be 
expressed to investigate functionality.   Cloning into expression vectorss would allow us 
to determine the protein function.  Cloning in itself would not necessarily assist in 
learning the function but would allow for further ‘knock down’ studies.  Knocking down 
a gene and observing phenotypical differences can lead to understanding the function.   
Knowing the function can help in determining if the gene contributes to pathogenicity or 
if it can be manipulated to assist in treatment.    
Lastly, genetic identification should be performed on the strains from both antigen preps 
T27K and CSS along with the techniques used to generate each.    Knowing if and what 
the genetic difference is between the two would allow an investigator to choose the one 
more closely resembling that of the human pathogen activity.  This would allow for 
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future in vitro studies which more closely resemble in vivo pathogen activity without 
harming the patient.   
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